

Intratympanic (IT) Therapies for Menière's Disease: Some Consensus Among the Confusion

Desi P. Schoo¹ · Grace X. Tan¹ · Matthew R. Ehrenburg¹ · Seth E. Pross¹ · Bryan K. Ward¹ · John P. Carey¹

Published online: 3 May 2017
© Springer Science+Business Media New York 2017

Abstract

Purpose of Review Aminoglycosides and corticosteroids are commonly used to treat Menière's disease. Intratympanic (IT) administration of these medications allows high inner ear concentrations without significant adverse systemic effects. As a direct result, IT therapy has grown in popularity. Recent studies have compared patient outcomes between IT aminoglycosides and corticosteroids. This review summarizes these findings.

Recent Findings Trials comparing IT corticosteroids to IT placebo or oral therapy have had conflicting results. Most recently, Lambert et al. investigated the effect of IT dexamethasone in a sustained-release formulation compared to placebo. Their findings demonstrated improvement in some secondary measures of vertigo with the sustained-release formulation. IT gentamicin is known to be effective in controlling vertigo in Menière's disease. In a recent study from 2016, Patel et al. compared IT gentamicin and IT methylprednisolone in a double-blind, randomized controlled trial and identified no significant differences between the two in vertigo control.

Summary IT injections of aminoglycosides and corticosteroids can improve vertigo control. Hearing and vestibular loss however may result with IT aminoglycosides. Corticosteroids

demonstrate limited hearing loss but may not have the same efficacy in controlling vertigo. Further investigation in the etiology of Menière's disease is needed to tailor the proposed treatment to suit the disease mechanism.

Keywords Menière's disease · Intratympanic · Aminoglycosides · Corticosteroids

Introduction

Menière's disease is a clinical syndrome where patients experience symptoms resulting from recurrent episodes of vertigo, hearing loss, and fluctuating aural fullness and tinnitus [1–3]. Prevalence estimates have varied with reports ranging from 3.5 to 513 affected individuals per 100,000 [4–6]. Patients with Menière's disease can experience impairments to overall quality of life [7] and disease-specific quality of life [8, 9].

Prosper Menière, for whom the disease is named, first reported in 1861 a syndrome of spinning vertigo that he attributed to hemorrhage within the membranous labyrinth. Despite these initial reports linking inner ear disorder to spinning vertigo, inner ear hemorrhage has not been identified as a common cause of the disease that bears his name. The pathophysiology of what we now call Menière's disease remains unknown. Endolymphatic hydrops, however, is a closely associated finding on temporal bone histology [10] and increasingly on contrast-enhanced magnetic resonance imaging as well [11, 12]. Since the cause(s) of Menière's disease is unknown, there are no ideal therapies [13]. Nevertheless, clinicians continue to offer a myriad of treatment options to patients with Menière's disease including restrictions on oral salt consumption, medical management with diuretics, steroids, or betahistine, and surgeries such as decompression of the endolymphatic sac [14••]. In a comprehensive review of the

Desi P. Schoo and Grace X. Tan are dual first authors.

This article is part of the Topical Collection on *Otology: Vestibular Disorders*

✉ Desi P. Schoo
dschoo1@jhmi.edu

¹ Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, 601 N. Caroline Street, Baltimore, MD 21287, USA

available literature, Torok reported study authors consistently identified improvements in 60–80% of patients regardless of the intervention used [15]. Few studies have observed the natural history of the disease, but among placebo-controlled studies, authors have reported over a 50% reduction in attack frequency at 9 months [16] and improvements in Menière's disease symptoms more broadly at 1 year [17].

In some patients with medically refractory recurrent vertigo, ablative therapies (which destroy labyrinthine function) can reduce the frequency of vertigo episodes but sacrifice or carry risk for injury to residual hearing and vestibular function in the treated ear. Intratympanic (IT) therapies for the treatment of Menière's disease have become increasingly popular among otologists. Previously, patients whose symptoms persisted despite medical therapies were offered ablative surgeries such as vestibular nerve section or surgical labyrinthectomy. Since their introduction [18], IT injections have been offered by otologists as a less invasive option which can spare the patient general anesthesia and potentially avoiding damage to the membranous labyrinth and cochlea. Aminoglycoside antibiotics, for instance, are chemicals well known to be vestibulotoxic to inner ear hair cells and can be administered without general anesthesia, as a transtympanic injected solution. Aminoglycosides, however, can also adversely affect hearing and are expected to cause vestibular impairment. For this reason, IT corticosteroids have gained popularity as a therapy which may be effective in reducing vertigo episode frequency, without permanently impairing inner ear function. Several recent reports have studied IT therapies including aminoglycosides such as streptomycin and gentamicin, and corticosteroids such as dexamethasone and methylprednisolone. This review will aim to synthesize the latest findings and provide clarity to the treating clinician where possible.

Intratympanic Therapies

Treatments involving the middle ear predate our current understanding of otologic anatomy and physiology. These first treatments likely occurred accidentally through the application of various medical concoctions into a draining ear (i.e., perforations) which penetrated the tympanic membrane accessing the middle ear. A comprehensive review of IT therapies by Lustig highlights several important advancements in our understanding of the middle ear space and the interventional opportunities its position plays between the external and inner ears [19]. Prior to the acceptance of administering medication through the tympanic membrane, surgically ablative approaches (i.e., labyrinthectomy or vestibular neurectomy) were commonly considered standard approaches for symptom control. Currently, these surgical approaches are typically reserved for refractory symptoms [14••, 20]. IT drug delivery, however, is not without some risk. Rauch et al. described a

1.6–3.9% risk of persistent perforation after treatment of sudden sensorineural hearing loss with IT corticosteroids [21, 22]. Other risks include local discomfort, inflammation (observed in guinea pigs after treatment with a sustained-release dexamethasone formulation [23]), otitis media or externa, transient vertigo caused by a caloric effect from the instilled fluid, and sensorineural hearing loss (from aminoglycosides). Today, treatment decisions are dependent on symptom severity and progression. Groups that have attempted to construct algorithms to streamline clinical decision-making [14••, 20] have emphasized using IT therapies early in the treatment pathway for Menière's disease, after lifestyle and dietary modification.

Aminoglycosides

Aminoglycoside antibiotics have a well-documented history of cochleotoxic and vestibulotoxic effects [24]. Within the bony labyrinth, several studies have investigated the trafficking and localization of aminoglycosides, finding different patterns of localization dependent upon the dose, duration, and route of administration. IT injected aminoglycosides appear to gain access to the inner ear via oval window and round window uptake [25, 26] through either active diffusion or endocytosis [27, 28]. Salt et al. recently quantified diffusion of gentamicin through the oval (35%) versus the round (57%) window [26, 29]. Access to these structures and their permeability, however, is not certain and may lead to variable exposure of drug to the inner ear [30–32]. Similar mechanisms of cellular trafficking (active diffusion and endocytosis) have been proposed in the transport of aminoglycosides into cells of the inner ear [33].

While most cells of the inner ear demonstrate aminoglycoside penetration, several studies have identified preferential loss of the inner hair cells at the basal turn of the cochlea and vestibular type I hair cells [34–38]. Direct damage to the spiral ganglion has also been observed [39], and histologic studies in rhesus monkeys suggest relative sparing of the maculae [40]. The degree to which a drug is cochleotoxic or vestibulotoxic differs among aminoglycosides. Gentamicin and streptomycin, for instance, are reported to be more vestibulotoxic. This feature has been used by otologists to control the vestibular symptoms of Menière's disease, initially provided through systemic delivery by Fowler [41] and subsequently through IT injections by Schuknecht [42, 43]. Use of streptomycin has been largely replaced by gentamicin, which is thought to be more selectively vestibulotoxic and better able to preserve residual hearing [44]. IT delivery of aminoglycosides is regularly used by otologists in the control of the fluctuating vestibular symptoms associated with Menière's disease.

IT Streptomycin

Described for the first time in 1944 [45], streptomycin was quickly adopted for chemical ablation of inner ear function. Five years after its introduction, streptomycin was administered intramuscularly by Fowler and Hamberger et al. for this purpose [41, 46]. In 1956, Schuknecht began reporting his experience with reported performing IT streptomycin injections. While 63% (5 of 8) of Menière's disease patients reported improvement in their vertigo, they also experienced profound sensorineural hearing loss [42, 43]. Use of IT streptomycin continued until Silverstein's 1979 review, which recommended abandoning streptomycin due to his experience in two patients with Menière's disease who had unpredictable responses and experiences with rapid hearing loss [47]. Similarly, Lange reported excellent control of vertigo (96%, 50 of 52 patients with complete vertigo control), but 24% experienced some degree of hearing loss posttreatment [48]. The rate of hearing loss prompted Lange's recommendation to administer gentamicin rather than streptomycin.

Occasional reports on the use of streptomycin for vertigo control have continued, although gentamicin has become the preferred aminoglycoside for chemical ablation of vestibular function. Jung and colleagues evaluated the quality of life (QOL) via the Menière's Disease Outcomes Questionnaire-Retrospective Version (MDOQ-R) after powdered streptomycin was applied to the middle ear space in patients with Menière's disease [49–51]. In addition to improvements in QOL, IT streptomycin yielded nearly a 59% complete control of vertigo (American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) class A (no vertigo)); however, this value is lower than rates of complete vertigo control reported by other studies in which IT gentamicin was used [52]. More recently, Kim et al. reasserted the use of powdered streptomycin directly applied to the round window [53]. They reported vertigo control in 83% of patients with 18% (18 of 98 patients) experiencing a greater than 10 dB HL hearing loss and 4 patients who experienced a greater than 30 dB HL hearing loss.

IT Gentamicin

Gentamicin has become the most commonly used aminoglycoside for treatment of vestibular symptoms associated with Menière's disease. While gentamicin is believed to be less cochleotoxic than streptomycin, some patients still develop hearing loss [33, 43]. A review of this institution's (Johns Hopkins Hospital) experience revealed 17% of patients treated with IT gentamicin experienced decreased hearing which were similar to patients treated conservatively [54]. This risk may be minimized by limiting the dose administered. Beck and Schmidt found that limiting the number of doses and by stopping treatment at the first sign of inner ear damage, rates

of hearing loss were decreased (hearing deterioration in 15 vs 58%) while vertigo symptoms (92.5 vs 95% with improved or resolved vertigo) and overall satisfaction with treatment (86 vs 95% satisfaction) were maintained [55]. Several groups subsequently reported their experiences with a variety of protocols altering dosing regimens or interval of treatment or by stopping at the onset of symptoms with varying degrees of success related to vertigo symptom control and hearing preservation [56–62]. Early protocols resulted in hearing loss rates ranging between 30 and 45% of patients receiving IT gentamicin, but these rates have decreased in newer protocols. One long-term (>2 years from treatment) follow-up study by Nedzelski reported vertigo control of AAO-HNS class A (i.e., no vertigo) in 84% of subjects and class B (i.e., vertigo attacks of 1–40% of pretreatment rate) in 8% of subjects with 26% experiencing worsening hearing [63]. Clinicians soon realized that the ototoxic effects of IT gentamicin were delayed 2–3 days which eventually led clinicians to develop titration protocols using fewer and less frequent injections and close monitoring for ototoxicity [64–67]. While this approach resulted in less hearing loss, perhaps as expected, there was slightly worse vertigo symptom control as well.

To date, there have only been a few interventional randomized controlled trials investigating the role of IT gentamicin in the treatment of Menière's disease. In 2011, Pullens and van Benthem reviewed the literature for the Cochrane Collaboration and identified seven interventional studies relating to IT gentamicin and Menière's disease [68]. Only two of these studies were randomized controlled trials (RCTs) and met all of their inclusion criteria to be accepted in their analysis. Similarly, in 2015, Syed and colleagues published a systematic review investigating randomized controlled trials of IT therapies for Menière's disease focusing on the same two randomized controlled trials [69]. In the first trial, Stokroos and Kingma reported results from their prospective randomized double-blind placebo-controlled trials establishing the efficacy of IT gentamicin compared to placebo in patients with active unilateral Menière's disease [70]. Using the titration method, injections were performed every 6 weeks until symptoms were controlled. They found IT gentamicin decreased the number of vertiginous attacks per year from 74 ± 114 pretreatment to 0 posttreatment ($p = 0.002$) compared to placebo (25 ± 31 and 11 ± 10 , $p = 0.028$) with no clinically significant change in hearing in either group at 6-month follow-up. However, Pullens and van Benthem noted significant heterogeneity in the number of vertiginous attacks in the pretreatment period (74 ± 114 attacks in the interventional group and 25 ± 31 in the placebo group reported in the year prior to inclusion) [71]. In a follow-up retrospective study in 2007 by the same group, the authors reported complete vertigo control in only 61.4% of patients and partial control in 19.3% of patients with a titration schedule of at least 27 days between injections [72].

In the second trial in the Cochrane review, Postema and colleagues similarly conducted a prospective, double-blind, randomized, placebo-controlled trial in patients with unilateral Menière's disease [73]. The authors also selected the titration method. In this study, a pressure equalization (PE) tube was placed 4 weeks prior to the start of therapy and 0.4 ml of 30 mg/ml gentamicin was administered weekly for 4 weeks. Data were collected on pure-tone audiometry and subjective evaluations of vertigo, aural fullness, and tinnitus rated on a 4-point scale: (3) severe, (2) moderate, (1) mild, and (0) none. There were decreases in both the aural fullness score (1.7 ± 1.0 [mean \pm SD] before to 0.9 ± 1.1 after study) and vertigo score (2.1 ± 0.8 before to 0.5 ± 0.6 after study) in the gentamicin group but no changes in the placebo group for aural fullness (1.8 ± 1.0 before to 1.8 ± 1.1 after treatment) or vertigo (2.0 ± 0.8 before to 1.8 ± 1.0 after treatment). Hearing levels and tinnitus did not significantly change in either group at the 12-month follow-up visit. The Cochrane Collaboration concluded IT gentamicin can be an effective treatment for vertigo in Menière's disease with a potential risk of hearing loss. There were recommendations for low-dosage administration with longer intervals between treatments [68].

Others performed more inclusive systematic reviews and meta-analyses with the goal of using all available prior data to determine the safety and effectiveness of IT gentamicin. [69, 74–77, 78•] In 2012, Huon et al. [77] published a comprehensive systematic review with meta-analysis. Reviewing available studies through 2011, the authors focused on studies investigating the use of IT gentamicin in randomized controlled trials ($n = 2$) and prospective cohort studies with greater than ten subjects ($n = 12$). They reported 87.5% (confidence interval 81.5–92.0%, $p < 0.001$) of patients achieved substantial vertigo control (AAO-HNS class A [71.4%] and class B [16.1%] vertigo control). When comparing fixed dose versus titration protocols, the authors reported successful symptom control in 87.5% (range, 56.3–97.5%) of patients receiving fixed doses and 88.2% (range, 71.0–97.1%) of those who followed a titration protocol without significant differences between groups ($p = 0.94$). In their systematic review, Cohen-Kerem et al. similarly found 90.7% substantial vertigo control (71.4% complete control) in their pooled meta-analysis and no differences between fixed dose and titration protocols [76]. Despite using similar source articles, Chia et al., however, found a significant difference between treatment approaches (fixed dosing versus titration) with titration protocols performing better at achieving complete vertigo control, 81.7 versus 66.7% [75].

Similar to the Huon et al. and Cohen-Kerem et al. reviews, Diamond and colleagues [74] also found no significant differences in vertigo symptom control between the two dosing approaches (fixed versus titration). The authors did note, however, a trend of increased hearing loss with more frequent dosing (e.g., 32% for dosing multiple times daily, 26% for

daily dosing, and 21% for weekly dosing). Huon et al. and Cohen-Kerem et al. found hearing was not significantly affected by either treatment paradigm (weighted mean PTA 2.2 [± 2.0] dB and 4.1 [± 2.9] dB for fixed and titration protocols, respectively, $p = 0.09$ [77]). Other findings from systematic reviews include better tinnitus control with the titration method ($p = 0.02$), equivocal improvements in aural fullness ($p = 0.06$), and overall improved QOL scores ($n = 7$ studies) [77]. From their review, Huon et al. [77] suggested that while a minimal cumulative dose of 13.4 mg may be predictive of treatment success, additional studies to determine optimal dosage, however, are needed.

Most recently, Vlastarakos et al. [78•] published a systematic review looking at sustained-release delivery of IT gentamicin (dynamic-release versus sustained-release vehicles). Dynamic release (microcatheter at the round window) was found to provide satisfactory vertigo control in 89.3% (70.9% reporting complete control). Sustained-release preparations (gentamicin-soaked wick/pledget) provided 82.2% satisfactory control in the pool patients (75% with complete control). In patients receiving sustained-release preparations, complete hearing loss was reported in 31.1% patients with another 23.3% of patients experiencing partial hearing loss. This adverse change in hearing was unacceptably high, reinforcing the suggestion of using a sustained-release vehicle only in patients who had failed IT gentamicin injections previously or those without serviceable hearing.

Corticosteroids

While the pathophysiology of Menière's disease is unknown, some have theorized Menière's disease may be immune-mediated [79], thereby providing a rationale for the use of immunosuppressive corticosteroids as a treatment. Further support was provided by the observation that IT injection of dexamethasone reduced endolymphatic hydrops as reflected by electrocochleography 1 month following treatment [80], a finding which was not sustained at 1-year follow-up [81]. This also suggested that patients with recurrent Menière's disease may require repeated treatments with IT steroids. Dexamethasone has also been shown to upregulate epithelial sodium transport, suggesting it may not be acting directly as an anti-inflammatory [82]. In an autoimmune mouse model, it was concluded that the inner ear mineralocorticoid effects are more likely to be responsible in preserving hearing rather than the glucocorticoid effects [83]. The first trials of IT dexamethasone for Menière's disease were conducted by Itoh and Sakata in the 1980s [84], and IT steroids have slowly gained popularity as a less invasive treatment compared to surgery and as an alternative to IT gentamicin.

IT steroid options include dexamethasone and methylprednisolone. Studies in guinea pigs showed IT injected methylprednisolone had higher inner ear fluid concentrations for

longer durations compared to dexamethasone [85] when corrected for anti-inflammatory potency. When comparing IT to intravenous (IV) corticosteroid administration in humans, both IT methylprednisolone and dexamethasone reached perilymph concentrations more than 200 times higher compared to IV administration [86]. As high-dose dexamethasone is not commonly available in many European countries, methylprednisolone (62.5 mg/ml) injections are often used instead [87••]. It should be noted that methylprednisolone is not favored by some authors due to burning discomfort often associated with application to the middle ear.

IT Methylprednisolone

Two retrospective studies of patients who underwent IT methylprednisolone injections reported at least short-term control of vertigo with variable long-term effects [88, 89]. Gabra and Saliba compared IT methylprednisolone to IT gentamicin retrospectively in 89 patients and showed better control of vertigo, tinnitus, and aural fullness with gentamicin [90].

In 2016, Patel and colleagues published a randomized, double-blind comparative effectiveness trial for 60 adults with refractory unilateral Menière's disease comparing two doses of IT 62.5 mg/ml methylprednisolone to IT 40 mg/ml gentamicin given 2 weeks apart [87••]. Their main outcome measure was vertigo frequency during months 18–24 after starting treatment compared to vertigo frequency during the 6 months prior to starting therapy. The authors reported equally effective vertigo control in each group. Specifically, there was an 87% reduction in vertigo frequency in the gentamicin group compared to a 90% reduction in the methylprednisolone group with similar mild adverse events. Though there was no difference in hearing levels, the gentamicin group demonstrated a decrease in speech discrimination. As expected, the gentamicin group experienced unilateral vestibular loss while the methylprednisolone group had preserved vestibular function. The study concluded that both IT methylprednisolone and gentamicin represent safe and effective therapeutic options for those with refractory unilateral Menière's disease.

IT Dexamethasone

Silverstein et al. carried out an early prospective, randomized, double-blind, placebo-controlled crossover study comparing IT 8 mg/ml dexamethasone with IT saline placebo in the 1990s [91]. A total of 20 patients received one intervention for three consecutive days and after 3 weeks switched to the other intervention for three consecutive days. The aim was to determine the effect of IT steroids on hearing loss and tinnitus. The study found no significant difference in these outcomes. However, none of the patients had disabling vertigo, and the frequency/severity of vertiginous episodes were not studied as outcome measures.

Garduño-Anaya and De Toledo [92] conducted a prospective, randomized, double-blind, placebo-controlled study comparing IT 4 mg/ml dexamethasone injections administered over five consecutive days to IT saline placebo in 22 patients. This study showed statistically significant improvements in vertigo control, subjective hearing loss, tinnitus, and aural fullness with IT dexamethasone. A Cochrane review in 2011 [93] noted this RCT as the only study to meet rigorous inclusion criteria but concluded there was limited evidence to support the effectiveness of IT steroids for the treatment of Menière's disease.

Since then, two systematic reviews of IT corticosteroid injections for Menière's disease have reviewed four other RCTs. Both reviews favored IT steroids as a treatment option [94]. Two trials additionally compared IT dexamethasone with gentamicin. One RCT comparing IT dexamethasone (4 mg/ml, three injections once every 3 days) with gentamicin showed a higher rate of vertigo control with gentamicin compared to dexamethasone without significant differences in hearing outcomes [95]. Another prospective, non-randomized study by Sennaroglu et al. compared instillation of five drops of 1 mg/ml dexamethasone through a PE tube every other day for 3 months with gentamicin [96]. While there was no difference in vertigo control between the two treatment groups, 13% of patients in the gentamicin arm suffered "total" hearing loss. Despite the potential increased rate of vertigo control with gentamicin, Lavigne et al. preferred dexamethasone to avoid the risk of cochleotoxicity with gentamicin [94].

Two other trials compared IT dexamethasone to medical therapy. Paragache et al. compared application of 0.2 mg/ml dexamethasone to the middle ear through a ventilation tube for 3 months and demonstrated no difference in vertigo control, tinnitus, or aural fullness compared to conventional medical therapy of dietary restriction and oral betahistine 16 mg three times daily [97]. Another study comparing IT high-dose 4 mg/ml dexamethasone every 3 days for three doses to high-dose 144 mg daily oral betahistine similarly showed no difference in vertigo and tinnitus control [98]. As a result, IT dexamethasone may be comparable to oral betahistine in treatment of Menière's disease with the benefit of achieving the same effect with a few quick procedures as opposed to a chronic daily medication. However, a recent multicenter, double-blind, randomized, placebo-controlled, dose-defining trial from Germany showed no difference in vertigo attacks between oral betahistine at a low dose (24 mg two times daily), high dose (48 mg three times daily), and placebo [16]. As such, oral betahistine and, by extension, IT dexamethasone may be working through a placebo effect.

Lack of consensus among studies regarding ideal dexamethasone administration frequency and dose may be responsible for the heterogeneity in outcomes. To determine the effect of administration frequency, one study compared

daily versus weekly IT 4 mg/ml dexamethasone administration and showed no significant difference in vertigo control [99]. To determine the effect of dose, a multicenter, randomized, double-blind, placebo-controlled trial compared a single IT injection of 12 and 3 mg dexamethasone in a timed-release gel to placebo and demonstrated reduced vertigo frequency with the 12 mg dose [100]. This trial also assessed the safety of a dexamethasone formulation in a glycol polymer which gels at body temperature, thereby allowing more sustained exposure of the inner ear to the steroid compared to an aqueous formulation. A phase 2b multicenter study compared a single IT injection of 12 mg dexamethasone of this sustained-release formulation to placebo. There was no statistically significant difference between the groups in the change from baseline vertigo rate and at month 3 follow-up (placebo [−43%], OTO-104 [−61%], $p = 0.067$) [101•]. There were improvements, however, in the number of days with definitive vertigo and daily vertigo counts [101•]. A phase 3 trial is currently ongoing. As such, the efficacy of dexamethasone may be an issue of appropriate dose and sufficient time of inner ear exposure to the drug.

Other IT Therapies

Other IT therapies used as therapy for Menière’s disease include antiviral agents such as ganciclovir [102] as recurrence of a neurotropic virus has been suggested to be an etiology of Menière’s disease. Even so, a prospective double-blind study showed no difference in outcomes. IT lidocaine for labyrinth anesthesia is another option with some retrospective studies suggesting efficacy [103]. However, no prospective, randomized controlled trial has been conducted. Latanoprost, commonly used to reduce intraocular pressure in glaucoma, may also act through the same receptors to decrease endolymphatic hydrops. It was studied in a small placebo-controlled, double-blind, crossover trial and showed improvement in vertigo and hearing compared to placebo [104]. Pinsetta et al. described the synthesis of a neamine-derived pseudodisaccharide which caused vestibular damage but spared the cochlea in an animal model [105]. This compound may be superior to gentamicin to circumvent gentamicin’s cochleotoxic effects, but to date, there have been no human trials.

Ongoing Clinical Trials

There are several prospective, double-blind, randomized, placebo-controlled clinical trials underway. According to the US National Institutes of Health Clinical Trials website (www.clinicaltrials.gov), several studies are focusing on IT injections for controlling vertigo frequency. As previously mentioned, a phase 2 prospective, double-blind, placebo-controlled clinical trial is evaluating the safety, efficacy,

Table 1 List of current clinical trials registered as recruiting on the ClinicalTrials.gov and NHS sites in 2017

Study	Principal investigator	Sites	Phase	Status	Study design	Population	Drug	Intervention method
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Menière’s Disease	Carl LeBel, Ph.D.	Multiple sites in the USA, and Europe	Phase 3	Recruiting	Randomized	Adults with unilateral Menière’s disease by 1995 AAO-HNS criteria	OTO-104 (dexamethasone sustained-release formulation) vs placebo	IT injection
Lamotrigine for Menière’s Disease: a Double-blind, Placebo-controlled Pilot Study	Lixin Zhang, M.D., Ph.D.	Dent Neuroscience Research Center, Amherst, NY	Phase 3	Recruiting	Randomized	Adults with unilateral Menière’s disease by 1995 AAO-HNS criteria	Lamotrigine vs placebo	Oral
Reduction of Plasma Vasopressin Level in Patients With Menière’s Disease	Tadashi Kitahara, M.D., Ph.D.	Osaka University, Suita city, Osaka, Japan	N/A	Recruiting	Randomized	Patients diagnosed as Menière’s disease patients according to the 1995 AAO-HNS criteria	None	Lifestyle
Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Menière’s Disease	Jonathan Kil, M.D.	Multiple sites in the USA (CA, NY, SC, WA)	Phase 1	Invitation	Randomized	By invitation, adults with unilateral Menière’s disease by 1995 AAO-HNS criteria	SPI-1005 (small molecule mimics glutathione peroxidase) vs placebo	Oral

and duration of action of IT latanoprost. According to phase 1 results, latanoprost significantly reduced vertigo in 30% of patients and improved speech discrimination scores in 15% of their participants compared to placebo. Those who received placebo, however, had a decrease in the intensity of their tinnitus whereas the latanoprost cohort did not [104]. Another ongoing trial is a multicenter, prospective, randomized, double-blind, placebo-controlled, phase 3 study of OTO-104 given as a single IT injection. There are several other clinical trials involving orally administered interventions; however, due to the scope of this article, their results have not been reported (Table 1).

Conclusions

A clinical diagnosis of Menière's disease is made with a patient history characterized by recurrent episodes of vertigo lasting 20 min or longer, typically accompanied by a low-frequency sensorineural hearing loss and fluctuating aural fullness and tinnitus. Most therapies are targeted at alleviating the symptoms of vertigo. For those who do not experience improvement in their symptoms with conservative medical management (e.g., low-salt diet, diuretics, betahistine), intratympanic injections of corticosteroids and aminoglycosides have been proven to provide benefit in reduction of vertigo frequency and other symptoms of Menière's disease. When dosed conservatively and using a titration schedule with infrequent dosing, IT gentamicin provides good control of vertiginous symptoms with minimal risk to hearing [69, 74–77]. Hearing loss and vestibular hypofunction, however, continue to be a risk of IT gentamicin due to its ablative nature and cochleotoxicity [69, 74–77, 78•]. Vestibular hypofunction is often associated with imbalance during rapid ipsilateral head movements and other symptoms such as oscillopsia [106, 107].

Studies are often hindered by the natural course of the disease, however, in which vertiginous symptoms tend to improve and hearing loss progressively worsens over time. Symptoms become less severe and disappear after 2–8 years in 60 to 80% of those suffering from the disease [108]. Patients often demonstrate variability in the severity of their symptoms and the degree of the end organ damage. Clinical trials which do not consider time to be a valid therapy and do not have a placebo arm to their study should be considered flawed [14••]. In addition, studies which do not recognize the tendency of patients to seek therapy when their symptoms are at their most severe create the illusion of therapeutic efficacy due to the intervention, all while ignoring the patient's symptomatic regression to his/her mean.

Acknowledgements This work was supported in part by NIH NIDCD grant T32DC000027. The authors would like to thank the Johns Hopkins Center for Hearing and Balance for their continued support.

Compliance with Ethical Standards

Conflict of Interest Dr. Desi P Schoo, Dr. Grace X Tan, Matthew R Ehrenburg, Dr. Seth E Pross, and Dr. Bryan K Ward declare that they have no conflicts of interest. Dr. John P Carey declares that he is a site investigator for a clinical trial of OTO-104 in Menière's disease.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
 - Of major importance
1. Committee on Hearing and Equilibrium. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease. *Otolaryngol Head Neck Surg.* 1995;113:181–5.
 2. Lopez-Escamez JA, Carey J, Chung W-H, et al. Diagnostic criteria for Menière's disease. *J Vestib Res.* 2015;25:1–7.
 3. Lambert PR, Carey J, Mikulec AA, LeBel C. Intratympanic sustained-exposure dexamethasone thermosensitive gel for symptoms of Ménière s disease. *Otol Neurotol.* 2016;37:1669–76.
 4. Alexander TH, Harris JP. Current epidemiology of Meniere's syndrome. *Otolaryngol Clin N Am.* 2010;43:965–70.
 5. Wladislavosky-Waserman P, Facer GW, Mokri B, Kurland LT. Meniere's disease: a 30-year epidemiologic and clinical study in Rochester, Mn, 1951-1980. *Laryngoscope.* 1984;94:1098–102.
 6. Havia M, Kentala E, Pyykkö I. Prevalence of Meniere's disease in general population of Southern Finland. *Otolaryngol Head Neck Surg.* 2005;133:762–8.
 7. Anderson JP, Harris JP. Impact of Meniere's disease on quality of life. *Otol Neurotol.* 2001;22:888–94.
 8. Söderman AC, Bergenius J, Bagger-Sjöbäck D, et al. Patients' subjective evaluations of quality of life related to disease-specific symptoms, sense of coherence, and treatment in Ménière's disease. *Otol Neurotol.* 2001;22:526–33.
 9. Green JD, Verrall A, Gates GA. Quality of life instruments in Meniere's disease. *Laryngoscope.* 2007;117:1622–8.
 10. Rauch SD, Merchant SN, Thedinger BA. Meniere's syndrome and endolymphatic hydrops: double-blind temporal bone study. *Ann Otol Rhinol Laryngol.* 1989;98:873–83.
 11. Nakashima T, Naganawa S, Sugiura M, et al. Visualization of endolymphatic hydrops in patients with Meniere's disease. *Laryngoscope.* 2007;117:415–20.
 12. Gürkov R, Flatz W, Louza J, et al. Herniation of the membranous labyrinth into the horizontal semicircular canal is correlated with impaired caloric response in Ménière's disease. *Otol Neurotol.* 2012;33:1375–9.
 13. Agrawal Y, Ward BK, Minor LB. Vestibular dysfunction: prevalence, impact and need for targeted treatment. *J Vestib Res.* 2013;23:113–7.

14. Sharon JD, Trevino C, Schubert MC, Carey JP. Treatment of Ménière's disease. *Curr Treat Options Neurol*. 2015;17:14. **This article provides a complete review of the current therapeutic options in the management of Ménière's disease. The treatment algorithm outlined in this paper is used by the authors of this review when caring for a patient with Ménière's disease.**
15. Torok N. Old and new in Ménière disease. *Laryngoscope*. 1977;87:1870–7.
16. Adrion C, Fischer CS, Wagner J, et al. Efficacy and safety of betahistine treatment in patients with Ménière's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). *BMJ*. 2016;352:h6816.
17. Thomsen J, Bretlau P, Tos M, Johnsen NJ. Placebo effect in surgery for Ménière's disease: a double-blind, placebo-controlled study on endolymphatic sac shunt surgery. *Arch Otolaryngol*. 1981;107:271–7.
18. Neville WS. Two cases of vertigo treated by intratympanic injection of alcohol. *Proc R Soc Med*. 1939;32:841.
19. Lustig LR. The history of intratympanic drug therapy in otology. *Otolaryngol Clin N Am*. 2004;37:1001–17.
20. Sajjadi H, Paparella MM. Ménière's disease. *Lancet*. 2008;372:406–14.
21. Rauch SD. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss. *JAMA*. 2011;305:2071.
22. Topf MC, Hsu DW, Adams DR, et al. Rate of tympanic membrane perforation after intratympanic steroid injection. *Am J Otolaryngol*. 2017;38:21–5.
23. Piu F, Wang X, Fernandez R, et al. OTO-104: a sustained-release dexamethasone hydrogel for the treatment of otic disorders. *Otol Neurotol*. 2011;32:171–9.
24. Rybak LP. Vestibular and auditory ototoxicity. In: Cummings otolaryngology—head and neck surgery. 2010. pp 2169–2178.
25. Smith BM, Myers MG. The penetration of gentamicin and neomycin into perilymph across the round window membrane. *Otolaryngol Head Neck Surg*. 1979;87:888–91.
26. Salt AN, Hartsock JJ, Gill RM, et al. Perilymph pharmacokinetics of locally-applied gentamicin in the guinea pig. *Hear Res*. 2016;342:101–11.
27. Goycoolea MV. Clinical aspects of round window membrane permeability under normal and pathological conditions. *Acta Otolaryngol*. 2001;121:437–47.
28. Becvarovski Z, Bojrab DI, Michaelides EM, et al. Round window gentamicin absorption: an in vivo human model. *Laryngoscope*. 2002;112:1610–3.
29. Salt AN, Ma Y. Quantification of solute entry into cochlear perilymph through the round window membrane. *Hear Res*. 2001;154:88–97.
30. Silverstein H, Rowan PT, Olds MJ, Rosenberg SI. Inner ear perfusion and the role of round window patency. *Am J Otol*. 1997;18:586–9.
31. Yoshioka M, Naganawa S, Sone M, et al. Individual differences in the permeability of the round window: evaluating the movement of intratympanic gadolinium into the inner ear. *Otol Neurotol*. 2009;30:645–8.
32. Alzamil KS, Linticum FH Jr. Extraneous round window membranes and plugs: possible effect on intratympanic therapy. *Ann Otol Rhinol Laryngol*. 2000;109:30–2.
33. Carey J. Intratympanic gentamicin for the treatment of Ménière's disease and other forms of peripheral vertigo. *Otolaryngol Clin N Am*. 2004;37:1075–90.
34. Wersall J, Lundquist P-G, Bjorkroth B. Ototoxicity of gentamicin. *J Infect Dis*. 1969;119:410–6.
35. Lindeman HH. Regional differences in sensitivity of the vestibular sensory epithelia to ototoxic antibiotics. *Acta Otolaryngol*. 1969;67:177–89.
36. de Groot JCMJ, Meeuwse F, Ruizendaal WE, Veldman JE. Ultrastructural localization of gentamicin in the cochlea. *Hear Res*. 1990;50:35–42.
37. Tsuji K, Velázquez-Villaseñor L, Rauch SD, et al. Temporal bone studies of the human peripheral vestibular system. Aminoglycoside ototoxicity. *Ann Otol Rhinol Laryngol Suppl*. 2000;181:20–5.
38. Lyford-Pike S, Vogelheim C, Chu E, et al. Gentamicin is primarily localized in vestibular type I hair cells after intratympanic administration. *J Assoc Res Otolaryngol*. 2007;8:497–508.
39. Bae WY, Kim LS, Hur DY, et al. Secondary apoptosis of spiral ganglion cells induced by aminoglycoside: Fas–Fas ligand signaling pathway. *Laryngoscope*. 2008;118:1659–68.
40. Sun DQ, Lehar M, Dai C, et al. Histopathologic changes of the inner ear in rhesus monkeys after intratympanic gentamicin injection and vestibular prosthesis electrode array implantation. *J Assoc Res Otolaryngol*. 2015;16:373–87.
41. Fowler EP Jr. Streptomycin treatment of vertigo. *Trans Am Acad Ophthalmol Otolaryngol*. 1948;52:293–301.
42. Schuknecht HF. Ablation therapy for the relief of Ménière's disease. *Trans Am Laryngol Rhinol Otol Soc*. 1956; 589–600.
43. Schuknecht HF. Ablation therapy in the management of Ménière's disease. *Acta Otolaryngol Suppl*. 1957;132:1–42.
44. Webster JC, McGee TM, Carroll R, et al. Ototoxicity of gentamicin. Histopathologic and functional results in the cat. *Trans Am Acad Ophthalmol Otolaryngol*. 1970;74:1155–65.
45. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria, 1944. *Clin Orthop Relat Res*. 2005; 3–6.
46. Hamberger C-A, Hydén H, Koch H. Streptomycin bei der Ménièreschen Krankheit. *Archiv für Ohren- Nasen- und Kehlkopfheilkunde*. 1949;155:667–82.
47. Silverstein H. Streptomycin treatment for Ménière's disease. *Ann Otol Rhinol Laryngol*. 1984;93:44–8.
48. Lange G. 27 years experiences with transtympanic aminoglycoside treatment of Ménière's disease. *Laryngorhinootologie*. 1995;74:720–3.
49. Jung J, Chun J, Kim N, et al. Evaluation of quality of life after intratympanic streptomycin injection in patients with Ménière's disease. *Otol Neurotol*. 2008;29:816–23.
50. Kato BM, Maya Kato B, LaRouere MJ, et al. Evaluating quality of life after endolymphatic sac surgery: the Ménière's Disease Outcomes Questionnaire. *Otol Neurotol*. 2004;25:339–44.
51. Murphy MP, Gates GA. Measuring the effects of Ménière's disease: results of the Patient-Oriented Severity Index (MD POSI) version 1. *Ann Otol Rhinol Laryngol*. 1999;108:331–7.
52. Berryhill WE, Graham MD. Chemical and physical labyrinthectomy for Ménière's disease. *Otolaryngol Clin N Am*. 2002;35:675–82.
53. Kim SH, Choi HS, Koh SH, et al. The reevaluation of a single low dose of streptomycin powder in chemical labyrinthectomy for Ménière's disease: our experience in ninety-eight patients. *Clin Otolaryngol*. 2012;37:491–6.
54. Wu IC, Minor LB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease. *Laryngoscope*. 2003;113:815–20.
55. Beck C, Schmidt CL. 10 years of experience with intratympanally applied streptomycin (gentamycin) in the therapy of Morbus Ménière. *Arch Otorhinolaryngol*. 1978;221:149–52.
56. Katzke D. Treatment of Ménière's disease with intratympanically applied gentamycin sulphate. *Laryngol Rhinol Otol*. 1982;61:4–8.

57. Blessing RE, Schlenter WW. Long-term results of gentamycin therapy of Ménière's disease. *Laryngorhinootologie*. 1989;68:657–60.
58. Möller C, Odkvist LM, Thell J, et al. Vestibular and audiologic functions in gentamicin-treated Ménière's disease. *Am J Otol*. 1988;9:383–91.
59. Ödkvist LM. Middle ear ototoxic treatment for inner ear disease. *Acta Otolaryngol*. 1988;105:83–6.
60. Laitakari K. Intratympanic gentamycin in severe Ménière's disease. *Clin Otolaryngol*. 1990;15:545–8.
61. Nedzelski JM, Schessel DA, Bryce GE, Pfleiderer AG. Chemical labyrinthectomy: local application of gentamicin for the treatment of unilateral Ménière's disease. *Am J Otol*. 1992;13:18–22.
62. Nedzelski JM, Chiong CM, Fradet G, et al. Intratympanic gentamicin instillation as treatment of unilateral Ménière's disease: update of an ongoing study. *Am J Otol*. 1993;14:278–82.
63. Kaplan DM, Nedzelski JM, Al-Abidi A, et al. Hearing loss following intratympanic instillation of gentamicin for the treatment of unilateral Ménière's disease. *J Otolaryngol*. 2002;31:106–11.
64. Magnusson M, Padoan S, Karlberg M, Johansson R. Delayed onset of ototoxic effects of gentamicin in patients with Ménière's disease. *Acta Otolaryngol*. 1991;111:120–2.
65. Magnusson M, Padoan S, Karlberg M, Johansson R. Delayed onset of ototoxic effects of gentamicin in treatment of Ménière's disease. *Acta Otolaryngol Suppl*. 1991;481:610–2.
66. Toth AA, Parnes LS. Intratympanic gentamicin therapy for Ménière's disease: preliminary comparison of two regimens. *J Otolaryngol*. 1995;24:340–4.
67. Atlas J, Parnes LS. Intratympanic gentamicin for intractable Ménière's disease: 5-year follow-up. *J Otolaryngol*. 2003;32:288.
68. Pullens B, van Benthem PP (2010) Intratympanic gentamicin for Ménière's disease or syndrome. *Cochrane Database Syst Rev*
69. Syed MI, Ilan O, Nassar J, Rutka JA. Intratympanic therapy in Ménière's syndrome or disease: up to date evidence for clinical practice. *Clin Otolaryngol*. 2015;40:682–90.
70. Stokroos R, Kingma H. Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Ménière's disease: a prospective, double-blind, placebo-controlled, randomized clinical trial. *Acta Otolaryngol*. 2004;124:172–5.
71. Pullens B, van Benthem PP. Intratympanic gentamicin for Ménière's disease or syndrome. *Cochrane Database Syst Rev*. 2011;3:CD008234.
72. De Beer L, Stokroos R, Kingma H. Intratympanic gentamicin therapy for intractable Ménière's disease. *Acta Otolaryngol*. 2007;127:605–12.
73. Postema RJ, Kingma CM, Wit HP, et al. Intratympanic gentamicin therapy for control of vertigo in unilateral Ménière's disease: a prospective, double-blind, randomized, placebo-controlled trial. *Acta Otolaryngol*. 2008;128:876–80.
74. Diamond C, Hornig JD, Liu R, O'Connell DA. Systematic review of intratympanic gentamicin in Ménière's disease. *J Otolaryngol*. 2003;32:351.
75. Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis. *Otol Neurotol*. 2004;25:544–52.
76. Cohen-Kerem R, Kisilevsky V, Einarson TR, et al. Intratympanic gentamicin for Ménière's disease: a meta-analysis. *Laryngoscope*. 2004;114:2085–91.
77. Huon L-K, Fang T-Y, Wang P-C. Outcomes of intratympanic gentamicin injection to treat Ménière's disease. *Otol Neurotol*. 2012;33:706–14.
78. Vlastarakos PV, Iacovou E, Nikolopoulos TP. Is gentamycin delivery via sustained-release vehicles a safe and effective treatment for refractory Ménière's disease? A critical analysis of published interventional studies. *Eur Arch Otorhinolaryngol*. 2017;274:1309–15. **This systematic review article examines the evidence for sustained-release intratympanic gentamicin in Ménière's disease. This article highlights the continued risk of hearing loss with the use of gentamicin noting that sustained-release formulations have an unacceptably high risk of complete or partial hearing loss.**
79. Greco A, Gallo A, Fusconi M, et al. Ménière's disease might be an autoimmune condition? *Autoimmun Rev*. 2012;11:731–8.
80. Martin-Sanz E, Luzardo CZ, Riesco LR, et al. The use of electrocochleography to monitor the response of Ménière's disease patients to intratympanic steroids. *Acta Otolaryngol*. 2013;133:1158–64.
81. Martin-Sanz E, Esteban-Sanchez J, Rodríguez-Riesco L, Sanz-Fernández R. Transitory effect on endolymphatic hydrops of the intratympanic steroids for Ménière's disease. *Laryngoscope*. 2015;125:1183–8.
82. Pondugula SR, Sanneman JD, Wangemann P, et al. Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel. *Am J Physiol Renal Physiol*. 2004;286:F1127–35.
83. Trune DR, Kempton JB, Gross ND. Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. *Hear Res*. 2006;212:22–32.
84. Itoh A, Sakata E. Treatment of vestibular disorders. *Acta Otolaryngol Suppl*. 1991;481:617–23.
85. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. *Laryngoscope*. 1999;109:1–17.
86. Bird PA, Begg EJ, Zhang M, et al. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. *Otol Neurotol*. 2007;28:1124–30.
87. Patel M, Agarwal K, Arshad Q, et al. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial. *Lancet*. 2016;388:2753–62. **This is a well-conducted randomized, double-blind, comparative effectiveness trial which elucidates the efficacy of vertigo control in patients with unilateral Ménière's disease using methylprednisolone or gentamicin.**
88. Dodson KM, Woodson E, Sismanis A. Intratympanic steroid perfusion for the treatment of Ménière's disease: a retrospective study. *Ear Nose Throat J*. 2004;83:394–8.
89. She W, Lv L, Du X, et al. Long-term effects of intratympanic methylprednisolone perfusion treatment on intractable Ménière's disease. *J Laryngol Otol*. 2015;129:232–7.
90. Gabra N, Saliba I. The effect of intratympanic methylprednisolone and gentamicin injection on Ménière's disease. *Otolaryngol Head Neck Surg*. 2013;148:642–7.
91. Silverstein H, Isaacson JE, Olds MJ, et al. Dexamethasone inner ear perfusion for the treatment of Ménière's disease: a prospective, randomized, double-blind, crossover trial. *Am J Otol*. 1998;19:196–201.
92. Garduño-Anaya MA, De Toledo HC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. *Head Neck Surg*. 2005;133(2):285–94.
93. Phillips JS, Westerberg B. Intratympanic steroids for Ménière's disease or syndrome. *Cochrane Database Syst Rev*. 2011;7:CD008514.
94. Lavigne P, Lavigne F, Saliba I. Intratympanic corticosteroids injections: a systematic review of literature. *Eur Arch Otorhinolaryngol*. 2016;273:2271–8.
95. Casani AP, Piaggi P, Cerchiai N, et al. Intratympanic treatment of intractable unilateral Ménière disease gentamicin or dexamethasone? A randomized controlled trial. *Otolaryngol Head Neck Surg*. 2012;146:430–7.

96. Sennaroglu L, Sennaroglu G, Gursel B, Dini FM. Intratympanic dexamethasone, intratympanic gentamicin, and endolymphatic sac surgery for intractable vertigo in Meniere's disease. *Otolaryngol Head Neck Surg.* 2001;125:537–43.
97. Paragache G, Panda NK, Raganathan M, Sridhara. Intratympanic dexamethasone application in Meniere's disease—is it superior to conventional therapy? *Indian J Otolaryngol Head Neck Surg.* 2005;57:21–3.
98. Albu S, Chirtes F, Trombitas V, et al. Intratympanic dexamethasone versus high dosage of betahistine in the treatment of intractable unilateral Meniere disease. *Am J Otolaryngol.* 2015;36:205–9.
99. Martin Sanz E, Zschaecck C, Christiane ZL, et al. Control of vertigo after intratympanic corticoid therapy for unilateral Ménière's disease: a comparison of weekly versus daily fixed protocols. *Otol Neurotol.* 2013;34:1429–33.
100. Lambert PR, Nguyen S, Maxwell KS, et al. A randomized, double-blind, placebo-controlled clinical study to assess safety and clinical activity of OTO-104 given as a single intratympanic injection in patients with unilateral Ménière's disease. *Otol Neurotol.* 2012;33:1257–65.
101. Lambert PR, Carey J, Mikulec AA, et al. Intratympanic sustained-exposure dexamethasone thermosensitive gel for symptoms of Ménière's disease: randomized phase 2b safety and efficacy trial. *Otol Neurotol.* 2016;37:1669–76. **This is a randomized, placebo-controlled trial which demonstrated the safety and efficacy of a novel sustained delivery system for intratympanic dexamethasone for non-ablative management of Ménière's disease.**
102. Guyot J-P, Maire R, Delaspre O. Intratympanic application of an antiviral agent for the treatment of Ménière's disease. *ORL J Otorhinolaryngol Relat Spec.* 2008;70:21–6. discussion 26–7
103. Verdonck J, Desloovere C. Intratympanic lidocaine instillation for Ménière's disease. *B-ENT.* 2011;7:157–64.
104. Rask-Andersen H, Friberg U, Johansson M, Stjernschantz J. Effects of intratympanic injection of latanoprost in Meniere's disease: a randomized, placebo-controlled, double-blind, pilot study. *Otolaryngol Head Neck Surg.* 2005;133:441–3.
105. Pinsetta FR, Kawano DF, de Carvalho MR, et al. Synthesis of neamine-based pseudodisaccharides as potential vestibulotoxic agents to treat vertigo in Ménière's disease. *Carbohydr Res.* 2013;373:97–102.
106. Carey JP, Minor LB, Peng GCY, et al. Changes in the three-dimensional angular vestibulo-ocular reflex following intratympanic gentamicin for Ménière's disease. *JARO - J Assoc Res Otolaryngol.* 2002;3:430–43.
107. Carey JP, Hirvonen T, Peng GCY, et al. Changes in the angular vestibulo-ocular reflex after a single dose of intratympanic gentamicin for Ménière's disease. *Ann N Y Acad Sci.* 2002;956:581–4.
108. Silverstein H, Smouha E, Jones R. Natural history vs. surgery for Meniere's disease. *Otolaryngol Head Neck Surg.* 1989;100:6–16.